• About
  • Subscribe
  • Advertise
  • Contact
Friday, June 13, 2025
Newsletter
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
No Results
View All Results
Home Local

Sector embraces government approval of standalone MIGS

by Myles Hume
May 11, 2020
in Glaucoma, Local, News, Therapies
Reading Time: 4 mins read
A A
Glaukos, which develops the iStent MIGS device, was involved in the successful application.

Glaukos, which develops the iStent MIGS device, was involved in the successful application.

Share on FacebookShare on Twitter

From this month, surgeons can perform standalone minimally invasive glaucoma surgery (MIGS) under Medicare, seeing Australia become the first major developed economy to universally approve the procedure in both public and private settings.

In the 2019-20 Mid-Year Economic and Fiscal Outlook, the Federal Government announced it would support a Medical Services Advisory Committee (MSAC) recommendation to list a new item for the insertion of micro-bypass glaucoma surgery (MBGS) devices – also known as MIGS. The item commenced on 1 May and is available to patients with open angle glaucoma for whom conservative treatment has failed or is contraindicated.

Ashish Agar.

It follows years of advocacy led by the Australian Society of Ophthalmologists (ASO) after a 2017 change in item number regulations threatened funding for all MIGS procedures.

The issue was partially addressed in October 2018 when the government approved a new item number, but limited its availability to those simultaneously undergoing cataract surgery. Ophthalmologists believed the measure did not go far enough because glaucoma patients not needing cataract surgery, or who had already had the operation, weren’t eligible.

“There are a few good stories to come out of this latest approval,” ASO vice-president and glaucoma surgeon Dr Ashish Agar, from the Prince of Wales Hospital in Sydney, told Insight.

“Firstly, Australia is leading the world now to allow this level of access to MIGS, as the first universal healthcare system in the world that will now allow this new technology as a standalone procedure.

“Secondly, it shows the system can work. We spend a lot of time criticising the Australian healthcare system, but this outcome demonstrates that if you approach an issue in a positive light as a team, and work hard through the process and technical work, we can achieve an excellent result for our patients.”

The ASO’s successful application to MSAC comprised a team including health economists Thema Consulting, industry (particularly Glaukos but also crucial data provided by Ivantis), with supporting statements from the Australia and New Zealand Glaucoma Society (ANZGS), RANZCO and Glaucoma Australia.

Agar said MSAC set the bar high in terms of evidence of the safety, effectiveness and cost of MIGS compared with other existing treatments such as trabeculectomy.

“And, as a result of that, we secured the approval but it has been designed to increase the level of science coming out the other end,” Agar said.

“This is not an all-comers process; patients will be screened for their eligibility and will have to meet specific criteria within the mechanism set up by RANZCO and ANZGS to ensure this process is followed.

“It also differs from a normal item number listing; this is a sophisticated approval where we are going to continue collecting data and outcomes and that will actually improve the evidence base going forward.”

At the time of writing, Agar said the ASO had not received documentation on the MBS fee for the procedure.

When it approved the item number last year, MSAC compared MIGS alongside trabeculectomy and concluded that although MIGS was slightly less effective, it was safer and may allow some patients to delay or avoid trabeculectomy.

Other analysis shows MIGS generally costs less than trabeculectomy, and is projected to save the MBS approximately $500,000 per annum by the fourth year of listing. This saving is driven by fewer initial and revision trabeculectomy services, however the true financial impact will depend on the efficacy of MIGS in reducing trabeculectomies, which is uncertain.

“MSAC will review the use of [MIGS] after two years to see what effect it has on the number of trabeculectomies being done and make sure it is still cost-effective,” the committee stated.

MSAC also supported establishing a registry to record outcomes.

Tags: ANZGSAustralia and New Zealand Glaucoma SocietAustralian Society of OphthalmologistsDr Ashish AgarGlaucoma AustraliaGlaukosIvantisMedical Services Advisory CommitteeMIGSminimally invasive glaucoma surgeryMSACPrince of Wales HospitalRANZCOThema Consultingtrabeculectomy

Related Posts

Advanced practice orthoptists Kylie Robinson (left) and Debra Gleeson have enjoyed the extra training and responsibility in the Eye and Ear pilot: Image: Eye and Ear.

Eye and Ear pilot gives orthoptists greater scope of practice

by Staff Writer
June 13, 2025

A new pilot program in the Royal Victorian Eye and Ear Hospital’s Acute Ophthalmology Services is boosting the clinic’s efficiency...

Victorian Virtual Specialist Consults

Optometrists can now access ophthalmology advice via Victorian Virtual Specialist Consults service

by Staff Writer
June 13, 2025

Optometrists can now access the Victorian Virtual Specialist Consults (VVSC) service for online access to an ophthalmologist for advice on...

The Dry Eye Society is holding training for its members in Brisbane in July.  Image: Pormezz/stock.adobe.com

Dry Eye Society announces wet lab training event

by Staff Writer
June 13, 2025

The Dry Eye Society has announced a members-only wet lab event, which will  deliver advanced, hands-on clinical training in dry eye management....

Join our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

Insight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.

Subscribe to our newsletter

View our privacy policy, collection notice and terms and conditions to understand how we use your personal information.

About Insight

  • About
  • Advertise
  • Subscribe
  • Contact
  • Terms & Conditions
  • Privacy Collection Notice
  • Privacy Policy

Popular Topics

  • Business
  • Feature
  • Research
  • Technology
  • Therapies
  • Classifieds

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

No Results
View All Results
NEWSLETTER
SUBSCRIBE
  • Latest News
  • All Sections
    • Ophthalmic insights
      • Policy & regulation
      • Company updates & acquisitions
      • Research
      • Clinical trials
      • Workforce
      • Product approvals
      • Conferences
      • Opinion
      • Indigenous eye health
      • Retail
    • Eye disease
      • Dry eye
      • Myopia
      • Cataract
      • Glaucoma
      • Macular disease – AMD
      • Diabetic eye disease
      • Inherited retinal disease
      • Corneal disease
      • Presbyopia
      • Eye infections
    • Ophthalmic Careers
      • New appointments
      • Industry profiles
      • Graduates
    • Ophthalmic organisations
      • Regulators
      • Optometry networks
      • Private ophthalmology clinics
      • Associations
      • Patient support bodies
      • Eye research institutions
      • Optometry schools
      • Optical Dispensing trainers
      • Medical schools
      • RANZCO
  • Features
    • Report
    • Soapbox
  • Ophthalmic education
    • CPD – Optometry
    • Optical Dispensing
    • Orthoptics Australia
    • Practice management
  • Products
    • Ophthalmic Treatments
      • Ophthalmic lenses
      • Lens treatments
      • Myopia interventions
      • Light-based therapy
      • Minimally invasive glaucoma surgery (MIGS)
      • Gene therapy
      • Laser treatments
      • Supplements
      • Eyewear & frames
      • Behavioural optometry/vision training
      • Contact lenses
      • Anti-VEGF
      • Intraocular lenses (IOLs)
      • Pharmaceuticals & consumables
    • Ophthalmic equipment & diagnostics
      • Biometry – axial length
      • Perimetry & visual fields
      • OCT
      • Phoropter
      • Autorefractor
      • Tonometry
      • Topography
      • Multimodal imaging
      • Retinal imaging
      • Anterior segment imaging
      • Software & data management
      • Microscopes
      • Slit lamps
      • Lens edging
      • Stands, chairs and tables
      • Ultrasound
      • Dry eye diagnostics
      • Low vision aids
  • Research
  • Classifieds
  • About Us
  • Advertise with Insight
  • Subscribe
  • Contact Insight

© 2025 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited